A press release today from Corbus Pharmaceuticals (Nasdaq: CRBP) announced the addition of Rachelle Jaques to the board of directors. After this appointment CRBP’s board consists of 7 highly qualified directors, 5 of which are independent.
Here are some interesting facts about Ms. Jaques mentioned in the press release:
- The CEO of Enzyvant Therapeutics; a private clinical stage biopharmaceutical company pursuing therapies for rare diseases.
- Previously served as the Senior Vice President and Global Complement Franchise head at Alexion Pharmaceuticals (Nasdaq: ALXN). There Ms. Jaques headed ALXN’s global commercialization strategy and implementation of rare disease therapies.
- Previously served as Vice President of U.S Hematology Marketing at Shire plc (Now part of Takeda).
- Previously served as Vice President of Business Operations at Baxalta.
Chairman of CRPB Board Of Directors Alan Holmer commented:
We are delighted to welcome Rachelle to our Board of Directors,…She brings an invaluable biopharmaceutical industry perspective toFrom CRBP Press Release
Corbusgained from her over a 25-year career. We look forward to benefiting from her exceptional insights into business operations as well as global and country-specific commercial marketing and sales as the Company lays the groundwork for its commercialization strategy.
Ms. Raques commented:
I have come to recognize and admire the pioneering workFrom CRBP Press Release
Corbusis undertaking in the development of treatments for rare inflammatory and fibrotic diseases, and I am excited to join a team that shares my dedication to patient-centric health solutions…I look forward to working with Corbus’ leadership team and my fellow directors as the Company develops its go-to-market commercial strategies ahead of topline results from several key studies in 2020.
CRBP CEO Yuval Cohen, Ph.D. added:
Rachelle is an accomplished biopharmaceutical executive with extensive commercial experience building and scaling successful drug franchises, and I am pleased to welcome her to our Board… She will be a real asset to our team as we bring our much-needed therapies to market and continue to advance our vision to become the leader in the treatment of inflammatory and fibrotic diseases by targeting the endocannabinoid system.From CRBP Press Release
Click here to Unlock Premium and #Join our trading team
MS Money Move and its Chief Operating Officer who is a scientist and individual investor, as well as its affiliates are not registered financial advisors. Our posts should serve as educational material to help you conduct due diligence research. Posts and articles are not directives or recommendations to invest in any security. We reserve the right to buy or sell any security for ourselves without any notification except when required by law. We are not responsible for the action of our affiliates. Investment theses may change due to the variable nature of the securities market. Because of this there is great risk when investing in stocks and options which can result is capital loss. Additionally, past performance by MS Money Moves or any security is not a predictor of future performance. Everyone should conduct their own research and due diligence before making an investment decision. We recommend you consult a financial advisor regarding any investment action.
The biotech sector is especially volatile. Stock prices may fluctuate substantially based on material or nonmaterial developments. We encourage everyone to familiarize themselves with clinical trial processes, relevant terminology, FDA/SEC rules and regulations, and the general processes of drug & therapy development/approval. Always do independent research in a security prior to investing.